July 27, 2022

Thank you to the V Foundation for Cancer Research and Parker Institute for Cancer Immunotherapy for generously supporting the Oldridge Lab through a Parker Bridge Fellowship! Your support reaffirms our commitment to seeking improved immunotherapies for deadly pediatric brain tumors.

Press Release: “Empowering Tomorrow’s Great Minds in Cancer Research: The Parker Institute for Cancer Immunotherapy Awards up to $4.5 Million to Nine Early Career Researchers”

June 26, 2020

Postdoc work (from Amy and Derek when we were both postdocs in Wherry Lab) profiling the heterogeneity of immune responses in COVID-19 patients admitted to the UPenn Health System is published in Science at the height of the COVID pandemic and cited in the New York Times:

NYTimes Article: “How the Coronavirus Short-Circuits the Immune System”

July, 2016

Building upon Derek’s PhD work (first genomic characterization of relapsed neuroblastoma, published in Nature Genetics), the Next Generation Personalized Neuroblastoma Therapy (NEPENTHE) trial begins under the leadership of Yael Mosse. This represents a huge milestone as the first precision medicine trial for relapsed neuroblastoma, offering hope for new therapies for previously untreatable and deadly pediatric cancers.

ClinicalTrials.gov: “Next Generation Personalized Neuroblastoma Therapy (NEPENTHE)”

Press Release: “The NEPENTHE Trial: Using Genetic Profiles to Assign Patients to Specific Treatment Strategies”

Nov 11, 2015

Derek’s PhD work uncovering causal mechanism by which non-coding variation affects neuroblastoma cancer initiation is published in Nature and recognized by the International Society for Pediatric Oncology (SIOP) with the 2015 Schweisguth Prize (awarded to “the author of the best scientific article by a trainee in the field of paedatric oncology”). Thank you SIOP for your support and reaffirming our deep commitment to pediatric cancer research!

Press Release: Change in a Single DNA Base Drives a Childhood Cancer